drugset / Trial / NCT04485585

A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.

NCT04485585

Phase 1 Completed 36 enrolled Boryung Pharmaceutical Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the influence of BR9006-1 and BR9006-2 on pharmacokinetics, safety, and tolerability when administered separately or co-administered to healthy male volunteers.

Timeline

Start
2020-07-20
Primary completion
2020-08-16
Completion
2020-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 50 mg
Subject Tamsulosin Other / unclassified 0.2 mg